NLS Pharmaceutics AG (NLSP)
1.94
-0.09 (-4.43%)
At close: Jan 15, 2025, 3:59 PM
2.00
3.08%
After-hours Jan 15, 2025, 04:21 PM EST
undefined% (undefined)
| Bid | 1.96 |
| Market Cap | 4.80M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -6.74 |
| PE Ratio (ttm) | -0.29 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 2 |
| Volume | 149,429 |
| Avg. Volume (20D) | 1,058,514 |
| Open | 2.01 |
| Previous Close | 2.03 |
| Day's Range | 1.94 - 2.07 |
| 52-Week Range | 1.73 - 20.80 |
| Beta | undefined |
About NLSP
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to ...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 29, 2021
Employees 6
Stock Exchange NASDAQ
Ticker Symbol NLSP
Website https://nlspharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for NLSP stock is "Hold." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
1 week ago ·
Source
+16.99%
NLS Pharmaceutics shares are trading higher after ...
Unlock content with
Pro Subscription
2 weeks ago ·
Source
+49.45%
NLS Pharmaceutics shares are trading higher after the company announced it filed an F-4 registration statement with the SEC ahead of a proposed merger.
